P7C3

• Description :

  P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H318

• Target :

  NAMPT

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/P7C3.html

• Purity :

  99.85

• Solubility :

  DMSO : ≥ 33 mg/mL

• Smiles :

  OC(CNC1=CC=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24

• Molecular Formula :

  C21H18Br2N2O

• Molecular Weight :

  474.19

• Precautions :

  H301, H318

• References & Citations :

  [1]Pieper AA et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010 Jul 9;142 (1) :39-51.|[2]Pieper AA et al. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev. 2014 Oct 7;43 (19) :6716-26.|[3]Chao Gu , et al. P7C3 Inhibits LPS-Induced Microglial Activation to Protect Dopaminergic Neurons Against Inflammatory Factor-Induced Cell Death in vitro and in vivo. Front Cell Neurosci. 2018; 12: 400.|[4]Blaya MO, Wasserman JM, Pieper AA, Sick TJ, Bramlett HM, Dietrich WD. Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. Neuropharmacology. 2019;145 (Pt B) :268-282.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [301353-96-8]